Corrigendum to "Myricetin Possesses Potential Protective Effects on Diabetic Cardiomyopathy through Inhibiting IκBα/NFκB and Enhancing Nrf2/HO-1".

[This corrects the article DOI: 10.1155/2017/8370593.].

In the article titled “Myricetin possesses potential protective effects on diabetic cardiomyopathy through inhibiting IκBα/NFκB and enhancing Nrf2/HO-1” [1], an error was identified in Figure 8(b) where the same original blots were mistakenly used for T-Nrf2 and HO-1 when preparing the image. The authors have provided the correct images for T-Nrf2 and HO-1 and the revised Figure 8 is as below:

Figure 1

Myricetin regulated the expression of Nrf2 and HO-1 in neonatal rat cardiomyocytes (NRCM). (a) Myricetin enhanced the expression and nuclei translocation of Nrf2 after 36 h treatment with or without high glucose. (b) Representative blots showed the expression of Nrf2 and HO-1. (c–e) Histogram showed the fold change of T-Nrf2, Nuc-Nrf2, and HO-1; all of the proteins were normalized to GAPDH or histone 3 before relative quantitative analysis, and all experiments were repeated 3 times independently. Data were presented as means ± SD. ∗P < 0.05 as compared with CON, and #P < 0.05 as compared with HG group.